bioRxivImmunology
Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain
L. Yang, M. Van Beek, Z. Wang, F. Muecksch, M. Canis, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, A. K. Chakraborty
Abstract
The Omicron variant of SARS-CoV-2 evades neutralization by most serum antibodies elicited by two doses of mRNA vaccines, but a third dose of the same vaccine increases anti-Omicron neutralizing antibodies. By combining computational modeling with data from vaccinated humans we reveal mechanisms underlying this observation. After the first dose, limited antigen availability in germinal centers results in a response dominated by B cells with high germline affinities for immunodominant epitopes that are significantly mutated in an Omicron-like variant. After the second dose, expansion of these memory cells and differentiation into plasma cells shape antibody responses that are thus ineffective for such variants. However, in secondary germinal centers, pre-existing higher affinity antibodies mediate enhanced antigen presentation and they can also partially mask dominant epitopes. These effects generate memory B cells that target subdominant epitopes that are less mutated in Omicron. The third dose expands these cells and boosts anti-variant neutralizing antibodies.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
- Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection
W. Wang, S. Lusvarghi, … C. D. Weiss·bioRxiv·Jul 5, 2022
- Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
F. Muecksch, Z. Wang, … M. Nussenzweig·bioRxiv·Feb 14, 2022
- Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
S. Lusvarghi, S. D. Pollett, … C. D. Weiss·bioRxiv·Dec 22, 2021
- mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
V.-V. Edara, K. E. Manning, … M. S. Suthar·bioRxiv·Dec 20, 2021